-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: January 2011
2010 Biotech Stock Performance
How did biotech stocks perform in 2010? It was a good year for the two most closely followed biotech stock indices, the NBI and BTK, as each outperformed the S&P 500 in 2010. However, in terms of breadth, only 49% of companies posted a gain for 2010 as seen in the first chart below. The 92 companies that started the year in the valuation range of $1M-$50M had a median return of -8%, a reversal Read More >
Innovation Alliance Event “Patents, Innovation and Job Creation: A Virtuous Circle”
An event is coming up on patents, innovation and job creation at the Newseum on Friday January 21. The keynote speakers are PTO Director David Kappos and Retired Chief Judge of the Federal Circuit Paul Michel. Other industry experts and executives will participate in panel discussions. Below is the news release. As the U.S. economy struggles with high unemployment, the Innovation Alliance hosts a half-day discussion with inventors, entrepreneurs, business leaders, and industry experts on the Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: David Kappos, economic development, economic growth, Events, Gene Quinn, Gregory Junemann, Hank Nothhaft, Harry Leonhardt, innovation, Innovation Alliance, job creation, Kim Hart, Lisa Kuuttila, patent, patents, Paul Michel, Robert Alt, United States Patent and Trademark Office, US Federal Circuit of Appeals, William Merritt
Tags: David Kappos, economic development, economic growth, Events, Gene Quinn, Gregory Junemann, Hank Nothhaft, Harry Leonhardt, innovation, Innovation Alliance, job creation, Kim Hart, Lisa Kuuttila, patent, patents, Paul Michel, Robert Alt, United States Patent and Trademark Office, US Federal Circuit of Appeals, William Merritt
Will Vilsack Let the Organic Tail Wag the Biotech Dog?
Forbes ran an opinion piece on January 5 authored by Henry Miller and Gregory Conko: Something is very wrong at the U.S. Department of Agriculture. The secretary, Tom Vilsack, is letting hypothetical claims by organic farmers – who produce less than 1 percent of the nation’s farming output – cripple an important and environmentally beneficial technology, the genetic engineering of crop plants. In December Vilsack announced that the USDA is considering geographic restrictions, as well Read More >
Don’t let politics and fear-mongering supersede science
The Wall Street Journal printed a letter-to-the-editor from Mary Boote, Executive Director for Truth About Trade and Technology. Mary’s letter ran in conjunction with one by U.S. Secretary of Agriculture Tom Vilsack regarding genetically engineered alfalfa and the issue of coexistence: The new rules for biotech alfalfa that Mr. Vilsack is considering, if enacted, would lead to a significant and costly reversal of previous policies. They would limit economic freedom and stifle scientific innovation, setting a precedent Read More >
IP Watchdog: Why Patents Matter
Great article in IP Watchdog of why patents matter. Highlights: -The article quotes a Patent Survey conducted by UC Berkeley School of Law which finds that: In fact, 67% of firms surveyed indicated that the existence of patents were an important factor in their investment decisions. And for those software folks who always want to incorrectly believe they don’t need funding, the figure was 60% for software companies. Higher were biotech companies (73%) and medical Read More >
